Company Analysis

AngioDynamics, Inc. (ANGO)

Nasdaq: ANGO · Surgical & Medical Instruments & Apparatus · Latham, NY · filing with the SEC since 2004
Grade5.4
◀ Past 5.5● Present 5.6▶ Future 5.0
1 est.
The companyfiscal 2026, as filed
Revenue$320M+9.5%
Net income-$36.7M-8.1%
Earnings per share$-0.88-6.0%
Operating cash flow$3.1M+130.5%
Cash$53.9M-3.6%
Debtn/a
Shareholders’ equity$171M-6.6%
Shares, diluted41.5M+1.6%
Return on equity-21.5%
The recordfrom its filings
Filings in 202651
Newest filingNov 4 · 4
Annual reportJul 14, 2026
Quarterly reportOct 8, 2026
Next report due10-Q by Jan 9
Insider sales, 12 months$700,000
Insider buys, 12 months$0.00
Patents granted327
Filer categoryAccelerated filer
Trailing twelve months to Aug 2026Revenue $325MNet income -$32.9MCash from operations $3.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
17181920212223242526
As filed, in USD. Nothing here is a forecast.

News

Nov 4, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 30, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 8, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Oct 8, 2026 · SEC EDGAR · Form DEFA14A
Extra proxy material
Open the filing on sec.gov
Oct 8, 2026 · SEC EDGAR · Form DEF 14A
Proxy statement
Open the filing on sec.gov
Oct 8, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Oct 8, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 29, 2026 · SEC EDGAR · Form 10-K/A
Annual report, amended
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ANGO · research, not advice